- Report
- October 2024
- 184 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- October 2024
- 186 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- May 2024
- 135 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1432EUR$1,500USD£1,199GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
- Report
- August 2022
- 120 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- April 2023
- 156 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- September 2022
- 152 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- April 2023
- 160 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- November 2023
- 189 Pages
Global
From €4295EUR$4,500USD£3,598GBP
The Disulfiram market is a segment of the Addiction Disorders Drugs market. Disulfiram is a medication used to treat alcohol use disorder (AUD). It works by blocking the breakdown of alcohol, causing unpleasant side effects when alcohol is consumed. It is used as an aid to help people abstain from drinking alcohol. Disulfiram is available in tablet form and is taken orally. It is also available in an injectable form.
The Disulfiram market is highly competitive, with many companies offering generic versions of the drug. Companies in the market include Mylan, Teva Pharmaceuticals, Sun Pharmaceuticals, Dr. Reddy's Laboratories, and Cipla. Show Less Read more